SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
170 hedge funds and large institutions have $955M invested in SANGAMO THERAPEUTICS INC in 2017 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 54 increasing their positions, 49 reducing their positions, and 20 closing their positions.
115% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 20
39% more call options, than puts
Call options by funds: $34.4M | Put options by funds: $24.7M
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
17% more capital invested
Capital invested by funds: $820M → $955M (+$136M)
15% more funds holding
Funds holding: 148 → 170 (+22)
10% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 49
0.7% more ownership
Funds ownership: 65.37% → 66.07% (+0.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$16.2M |
| 3 |
AC
Alexandria Capital
Arlington,
Virginia
|
+$13.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.15M |
| 5 |
PP
PDT Partners
New York
|
+$7.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$18.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.9M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$11.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.4M |
| 5 |
Millennium Management
New York
|
-$9.9M |
SGMO Hedge Fund Activity: Q4 2017 in Review
170 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q4 2017, worth a combined $955M — up 17% from $820M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new SGMO positions and 20 closed out — a net gain of 23 holders — while 54 added to existing stakes and 49 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $37.4M. The largest seller was RA Capital Management, exiting entirely with an estimated $18.8M sold.
- 170 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q4 2017, up from 148 in Q3 2017.
- Funds reported $955M of SANGAMO THERAPEUTICS INC stock for Q4 2017, up 17% quarter-over-quarter.
- 43 funds opened new SANGAMO THERAPEUTICS INC positions in Q4 2017 and 20 closed out, a net change of +23 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q4 2017 was Fidelity Investments, an estimated $37.4M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q4 2017 was RA Capital Management, an estimated $18.8M sold.
Based on aggregated 13F filings for Q4 2017.